Compare SIMO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | ACAD |
|---|---|---|
| Founded | 1995 | 1993 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2005 | 2000 |
| Metric | SIMO | ACAD |
|---|---|---|
| Price | $128.08 | $21.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 22 |
| Target Price | ★ $114.38 | $30.55 |
| AVG Volume (30 Days) | 456.0K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $42.27 | $18.90 |
| Revenue Next Year | $12.78 | $11.62 |
| P/E Ratio | $36.09 | ★ $9.81 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $37.87 | $14.08 |
| 52 Week High | $146.85 | $28.35 |
| Indicator | SIMO | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 59.38 | 46.16 |
| Support Level | $126.80 | $21.51 |
| Resistance Level | $145.77 | $22.03 |
| Average True Range (ATR) | 6.65 | 0.72 |
| MACD | 1.61 | 0.19 |
| Stochastic Oscillator | 90.68 | 51.38 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid state storage devices. Its only operating segment is to develop NAND flash controllers and SSDs solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.